<i>In Vitro</i> Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of <i>Mycobacterium abscessus</i>

Abstract

Tigecycline is used in multidrug regimens for salvage therapy of <i>Mycobacterium abscessus</i> infections but is often poorly tolerated and has no oral formulation. Here, we report similar <i>in vitro</i> activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of <i>M. abscessus</i> complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for <i>M. abscessus</i> infections.